Lenvatinib + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer (DTC)
Conditions
Differentiated Thyroid Cancer (DTC)
Trial Timeline
Jan 11, 2017 → Dec 29, 2021
NCT ID
NCT02966093About Lenvatinib + Placebo
Lenvatinib + Placebo is a phase 3 stage product being developed by Eisai for Differentiated Thyroid Cancer (DTC). The current trial status is completed. This product is registered under clinical trial identifier NCT02966093. Target conditions include Differentiated Thyroid Cancer (DTC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02966093 | Phase 3 | Completed |
Competing Products
20 competing products in Differentiated Thyroid Cancer (DTC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| Selpercatinib Monotherapy | Eli Lilly | Phase 2 | 52 |
| Selumetinib + Placebo + Radioactive Iodine Therapy | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 52 |
| Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo | Novartis | Phase 3 | 77 |
| PDR001 | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| sunitinib | Pfizer | Approved | 84 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 76 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 76 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Larotrectinib monotherapy | Bayer | Phase 2 | 49 |